Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lattice SFRT plus enlonstobart for recurrent or metastatic bulky gynecologic malignancies
ChiCTR2500101866Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PBI-1308 in gynecological cancer, sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
PBI-1308
03
Conditions
gynecological cancer
Beyond the preview
Go deeper on ChiCTR2500101866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101866.